首页> 外文期刊>The lancet oncology >Chemoprevention of lung cancer.
【24h】

Chemoprevention of lung cancer.

机译:化学预防肺癌。

获取原文
获取原文并翻译 | 示例
           

摘要

Lung cancer is a major cause of mortality and morbidity worldwide. Overall survival has only improved slightly despite advances in surgery, radiotherapy, and chemotherapy. Molecularly targeted agents are currently being studied in all treatment settings including that of chemoprevention, which is defined as the use of natural or synthetic agents to interrupt the process of carcinogenesis and to prevent or delay tumour occurrence. Lung cancer has become an increasingly difficult problem to treat with standard therapies and chemopreventive strategies have been developed. Progress in chemoprevention is reliant on the collaborative efforts of researchers in basic science and clinical settings who study the biology of lung cancer with the goal of uncovering new mechanisms of carcinogenesis. Small molecules which target specific receptors or mutations such as inhibitors of epidermal growth factor receptor or RAS will have an increasingly significant role as they are associated with more tolerable side-effects and may prove more effective. Development of a risk model with intermediate endpoints is essential for future chemoprevention studies.
机译:肺癌是世界范围内死亡率和发病率的主要原因。尽管手术,放疗和化疗取得了进步,但总体生存率仅略有提高。分子靶向药物目前正在包括化学预防在内的所有治疗环境中进行研究,化学预防被定义为使用天然或合成药物中断癌变过程并预防或延迟肿瘤的发生。肺癌已经成为越来越难以通过标准疗法治疗的问题,并且已经开发出化学预防策略。化学预防的进展依赖于基础科学和临床研究人员在研究肺癌生物学方面的共同努力,目的是发现新的致癌机制。靶向特定受体或突变的小分子,例如表皮生长因子受体或RAS抑制剂,将具有越来越重要的作用,因为它们与更可耐受的副作用相关,并且可能被证明更有效。具有中间终点的风险模型的开发对于将来的化学预防研究至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号